There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 89bio (ETNB – Research Report) and Evolus (EOLS – Research Report) with bullish sentiments.
89bio (ETNB)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on 89bio today and set a price target of $32.00. The company’s shares closed last Wednesday at $10.79.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
89bio has an analyst consensus of Strong Buy, with a price target consensus of $28.67.
See Insiders’ Hot Stocks on TipRanks >>
Evolus (EOLS)
Needham analyst Serge Belanger maintained a Buy rating on Evolus today and set a price target of $22.00. The company’s shares closed last Wednesday at $9.91.
According to TipRanks.com, Belanger is ranked 0 out of 5 stars with an average return of
Evolus has an analyst consensus of Strong Buy, with a price target consensus of $22.80, a 124.9% upside from current levels. In a report issued on December 17, Mizuho Securities also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ETNB:
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 89bio 15.135M share Spot Secondary priced at $9.25
- 89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 89bio announces upsized pricing of $150M public offering
